• Something wrong with this record ?

Complex methodology for rational design of Apremilast-benzoic acid co-crystallization process

J. Jirát, D. Ondo, M. Babor, L. Ridvan, M. Šoóš,

. 2019 ; 570 (-) : 118639. [pub] 20190826

Language English Country Netherlands

Document type Journal Article

A new co-crystal of pharmaceutical active ingredient Apremilast was successfully designed in this work. The discovered co-crystal with benzoic acid significantly improves key properties like the dissolution and stability of an otherwise poorly soluble Apremilast. A crystallization process was developed, which includes efficient solvent selection and ternary phase diagram construction to minimize risks during scale up. To increase efficiency, we propose that both steps be combined into a single methodology based on solubility data. A suitable solvent for the co-crystallization process was selected and ternary phase diagrams were constructed using three different modifications of thermodynamic model of solid-liquid equilibria. Based on the obtained information, the co-crystallization process was scaled-up to 100 mL. This provides a feasible process to produce larger amounts of this promising pharmaceutical solid form of Apremilast necessary for further drug development.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005972
003      
CZ-PrNML
005      
20200527082159.0
007      
ta
008      
200511s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijpharm.2019.118639 $2 doi
035    __
$a (PubMed)31465834
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Jirát, Jan $u Department of Chemical Engineering, University of Chemistry and Technology, Technická 3, 166 28 Prague 6 - Dejvice, Czech Republic.
245    10
$a Complex methodology for rational design of Apremilast-benzoic acid co-crystallization process / $c J. Jirát, D. Ondo, M. Babor, L. Ridvan, M. Šoóš,
520    9_
$a A new co-crystal of pharmaceutical active ingredient Apremilast was successfully designed in this work. The discovered co-crystal with benzoic acid significantly improves key properties like the dissolution and stability of an otherwise poorly soluble Apremilast. A crystallization process was developed, which includes efficient solvent selection and ternary phase diagram construction to minimize risks during scale up. To increase efficiency, we propose that both steps be combined into a single methodology based on solubility data. A suitable solvent for the co-crystallization process was selected and ternary phase diagrams were constructed using three different modifications of thermodynamic model of solid-liquid equilibria. Based on the obtained information, the co-crystallization process was scaled-up to 100 mL. This provides a feasible process to produce larger amounts of this promising pharmaceutical solid form of Apremilast necessary for further drug development.
650    _2
$a kyselina benzoová $x chemie $7 D019817
650    _2
$a krystalizace $x metody $7 D003460
650    _2
$a rozpustnost $x účinky léků $7 D012995
650    _2
$a rozpouštědla $x chemie $7 D012997
650    _2
$a thalidomid $x analogy a deriváty $x chemie $7 D013792
650    _2
$a termodynamika $7 D013816
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ondo, Daniel $u Department of Physical Chemistry, University of Chemistry and Technology, Technická 5, 166 28 Prague 6 - Dejvice, Czech Republic.
700    1_
$a Babor, Martin $u Zentiva, k.s., U Kabelovny 130, 10237 Prague 10, Czech Republic; Department of Solid State Chemistry, University of Chemistry and Technology, Technická 5, 166 28 Prague 6 - Dejvice, Czech Republic.
700    1_
$a Ridvan, Luděk $u Zentiva, k.s., U Kabelovny 130, 10237 Prague 10, Czech Republic.
700    1_
$a Šoóš, Miroslav $u Department of Chemical Engineering, University of Chemistry and Technology, Technická 3, 166 28 Prague 6 - Dejvice, Czech Republic. Electronic address: miroslav.soos@vscht.cz.
773    0_
$w MED00002359 $t International journal of pharmaceutics $x 1873-3476 $g Roč. 570, č. - (2019), s. 118639
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31465834 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200527082156 $b ABA008
999    __
$a ok $b bmc $g 1524830 $s 1096028
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 570 $c - $d 118639 $e 20190826 $i 1873-3476 $m International journal of pharmaceutics $n Int. j. pharm. $x MED00002359
LZP    __
$a Pubmed-20200511

Find record

Citation metrics

Logged in users only

Archiving options

Loading data ...